Novel therapeutic approaches for diabetic nephropathy and retinopathy

Pharmacological Research

Volumn 98, Issue , 2015, Pages 39-44

  Usuelli, Vera ^a   La Rocca, Ennio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Diabetic nephropathy; Diabetic retinopathy; Hyperglycemia; Microvascular complications; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSTERONE ANTAGONIST; ALLOPURINOL; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; BARDOXOLONE METHYL; BEVASIRANIB; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTOXIFYLLINE; PLACEBO; RAPAMYCIN; RUBOXISTAURIN; SPIRONOLACTONE; VASCULOTROPIN INHIBITOR;

BLINDNESS; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DYSLIPIDEMIA; END STAGE RENAL DISEASE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LOW DRUG DOSE; MACROALBUMINURIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VITRECTOMY; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; PROCEDURES;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; PANCREAS TRANSPLANTATION;

EID: 84930763554     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.10.003     Document Type: Review

References (66)

1. F. Folli, V. Guzzi, L. Perego, D.K. Coletta, G. Finzi, and C. Placidi Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation PLoS ONE 5 3 2010 e9923
2. E.W. Gregg, Y. Li, J. Wang, N.R. Burrows, M.K. Ali, and D. Rolka Changes in diabetes-related complications in the United States, 1990-2010 N Engl J Med 370 April (16) 2014 1514 1523
3. G. Perseghin, P. Fiorina, F. De Cobelli, P. Scifo, A. Esposito, and T. Canu Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study J Am Coll Cardiol 46 September (6) 2005 1085 1092
4. R. Paroni, I. Fermo, P. Fiorina, and G. Cighetti Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects Amino Acids 28 June (4) 2005 389 394
5. E. Astorri, P. Fiorina, G. Gavaruzzi, A. Astorri, and G. Magnati Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment Cardiology 88 March-April (2) 1997 152 155
6. M. Brownlee The pathobiology of diabetic complications: a unifying mechanism Diabetes 54 June (6) 2005 1615 1625
7. A. Mima Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets J Diabetes Res 2013 2013 248563
8. S.S. Badal, and F.R. Danesh New insights into molecular mechanisms of diabetic kidney disease Am J Kidney Dis 63 February (2 Suppl. 2) 2014 S63 S83
9. A. Doria, M.A. Niewczas, and P. Fiorina Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol 32 September (5) 2012 437 444
10. M.B. Duran-Salgado, and A.F. Rubio-Guerra Diabetic nephropathy and inflammation World J Diabetes 5 June (3) 2014 393 398
11. B.M. Chavers, R.W. Bilous, E.N. Ellis, M.W. Steffes, and S.M. Mauer Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria N Engl J Med 320 April (15) 1989 966 970
12. M.E. Williams New potential agents in treating diabetic kidney disease: the fourth act Drugs 66 18 2006 2287 2298
13. M.E. Cooper Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy Diabetologia 44 November (11) 2001 1957 1972
14. M.C. Thomas, C. Tikellis, W.M. Burns, K. Bialkowski, Z. Cao, and M.T. Coughlan Interactions between renin angiotensin system and advanced glycation in the kidney J Am Soc Nephrol 16 October (10) 2005 2976 2984
15. S. Devaraj, A.T. Cheung, I. Jialal, S.C. Griffen, D. Nguyen, and N. Glaser Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications Diabetes 56 November (11) 2007 2790 2796
16. S. Nishimura, I. Manabe, M. Nagasaki, K. Eto, H. Yamashita, and M. Ohsugi CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity Nat Med 15 August (8) 2009 914 920
17. J.C. Pickup, M.B. Mattock, G.D. Chusney, and D. Burt NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X Diabetologia 40 November (11) 1997 1286 1292
18. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 329 14 1993 977 986
19. I.H. de Boer Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study Diabetes Care 37 January (1) 2014 24 30
20. P. Fiorina, M. Venturini, F. Folli, C. Losio, P. Maffi, and C. Placidi Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation Diabetes Care 28 June (6) 2005 1303 1310
21. P. Fioretto, M.W. Steffes, D.E. Sutherland, F.C. Goetz, and M. Mauer Reversal of lesions of diabetic nephropathy after pancreas transplantation N Engl J Med 339 July (2) 1998 69 75
22. G. Viberti, C.E. Mogensen, L.C. Groop, and J.F. Pauls Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group JAMA 271 January (4) 1994 275 279
23. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, and H.H. Parving Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 September (12) 2001 861 869
24. R.A. Santos, A.J. Ferreira, T. Verano-Braga, and M. Bader Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system J Endocrinol 216 February (2) 2013 R1 R17
25. S.E. Bursell, A.C. Clermont, L.P. Aiello, L.M. Aiello, D.K. Schlossman, and E.P. Feener High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes Diabetes Care 22 August (8) 1999 1245 1251
26. S. Yusuf, G. Dagenais, J. Pogue, J. Bosch, and P. Sleight Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators N Engl J Med 342 January (3) 2000 154 160
27. E. Dounousi, E. Papavasiliou, A. Makedou, K. Ioannou, K.P. Katopodis, and A. Tselepis Oxidative stress is progressively enhanced with advancing stages of CKD Am J Kidney Dis 48 November (5) 2006 752 760
28. P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, and E.B. Grossman Bardoxolone methyl and kidney function in CKD with type 2 diabetes N Engl J Med 365 July (4) 2011 327 336
29. B.B. McCormick, A. Sydor, A. Akbari, D. Fergusson, S. Doucette, and G. Knoll The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis Am J Kidney Dis 52 September (3) 2008 454 463
30. R.E. Gilbert, S.A. Kim, K.R. Tuttle, G.L. Bakris, R.D. Toto, and J.B. McGill Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes Diabetes Care 30 April (4) 2007 995 996
31. A. Mima, J. Hiraoka-Yamomoto, Q. Li, M. Kitada, C. Li, and P. Geraldes Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes Diabetes 61 November (11) 2012 2967 2979
32. A. Mima, M. Kitada, P. Geraldes, Q. Li, M. Matsumoto, and K. Mizutani Glomerular VEGF resistance induced by PKCdelta/SHP-1 activation and contribution to diabetic nephropathy FASEB J 26 July (7) 2012 2963 2974
33. T. Xiao, X. Guan, L. Nie, S. Wang, L. Sun, and T. He Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice Mol Cell Biochem 394 September (1-2) 2014 145 154
34. K. Nagai, T. Matsubara, A. Mima, E. Sumi, H. Kanamori, and N. Iehara Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy Kidney Int 68 August (2) 2005 552 561
35. P. Maffi, F. Bertuzzi, F. De Taddeo, P. Magistretti, R. Nano, and P. Fiorina A. Secchi Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy Diabetes Care 30 May (5) 2007 1150 1155
36. P. Fiorina, A. Vergani, R. Bassi, M.A. Niewczas, M.M. Altintas, and M.G. Pezzolesi Role of podocyte B7-1 in diabetic nephropathy J Am Soc Nephrol 25 July (7) 2014 1415 1429
37. C.C. Yu, A. Fornoni, A. Weins, S. Hakroush, D. Maiguel, and J. Sageshima Abatacept in B7-1-positive proteinuric kidney disease N Engl J Med 369 December (25) 2013 2416 2423
38. D.M. Maahs, L. Caramori, D.Z. Cherney, A.T. Galecki, C. Gao, and D. Jalal Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study Curr Diab Rep 13 August (4) 2013 550 559
39. A. Sato, K. Hayashi, M. Naruse, and T. Saruta Effectiveness of aldosterone blockade in patients with diabetic nephropathy Hypertension 41 January (1) 2003 64 68
40. S. Bianchi, R. Bigazzi, and V.M. Campese Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study Am J Kidney Dis 46 July (1) 2005 45 51
41. K. Rossing, K.J. Schjoedt, U.M. Smidt, F. Boomsma, and H.H. Parving Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study Diabetes Care 28 September (9) 2005 2106 2112
42. N.G. Congdon, D.S. Friedman, and T. Lietman Important causes of visual impairment in the world today JAMA 290 October (15) 2003 2057 2060
43. J.C. Yam, and A.K. Kwok Update on the treatment of diabetic retinopathy Hong Kong Med J 13 February (1) 2007 46 60
44. N. Cheung, P. Mitchell, and T.Y. Wong Diabetic retinopathy Lancet 376 July (9735) 2010 124 136
45. R.B. Caldwell, M. Bartoli, M.A. Behzadian, A.E. El-Remessy, M. Al-Shabrawey, and D.H. Platt Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress Curr Drug Targets 6 June (4) 2005 511 524
46. M.J. Sheetz, and G.L. King Molecular understanding of hyperglycemia's adverse effects for diabetic complications JAMA 288 November (20) 2002 2579 2588
47. W. Zhang, H. Liu, M. Rojas, R.W. Caldwell, and R.B. Caldwell Anti-inflammatory therapy for diabetic retinopathy Immunotherapy 3 May (5) 2011 609 628
48. J.A. Davidson, T.A. Ciulla, J.B. McGill, K.A. Kles, and P.W. Anderson How the diabetic eye loses vision Endocrine 32 August (1) 2007 107 116
49. F. Bandello, R. Lattanzio, I. Zucchiatti, and C. Del Turco Pathophysiology and treatment of diabetic retinopathy Acta Diabetol 50 February (1) 2013 1 20
50. A. Das, S. Stroud, A. Mehta, and S. Rangasamy New treatments of diabetic retinopathy Diabetes Obes Metab August 2014 10.1111/dom.12384
51. R. Simo, and C. Hernandez Advances in the medical treatment of diabetic retinopathy Diabetes Care 32 August (8) 2009 1556 1562
52. R.A. Cohen, C.H. Hennekens, W.G. Christen, A. Krolewski, D.M. Nathan, and M.J. Peterson Determinants of retinopathy progression in type 1 diabetes mellitus Am J Med 107 July (1) 1999 45 51
53. M.F. Lopes-Virella, N.L. Baker, K.J. Hunt, T.J. Lyons, A.J. Jenkins, and G. Virella High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes Diabetes Care 35 June (6) 2012 1333 1340
54. T.D. Panagiotoglou, E.S. Ganotakis, G.D. Kymionis, J.A. Moschandreas, G.N. Fanti, and S.K. Charisis Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol Ophthalmic Surg Lasers Imaging 41 May-June (3) 2010 316 322
55. M.S. Ola, M.M. Ahmed, H.M. Abuohashish, S.S. Al-Rejaie, and A.S. Alhomida Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats Neurochem Res 38 August (8) 2013 1572 1579
56. N. Chaturvedi, M. Porta, R. Klein, T. Orchard, J. Fuller, and H.H. Parving Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet 372 October (9647) 2008 1394 1402
57. A.C. Keech, P. Mitchell, P.A. Summanen, J. O'Day, T.M. Davis, and M.S. Moffitt Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 November (9600) 2007 1687 1697
58. J.F. Arevalo, J.G. Sanchez, A.F. Lasave, L. Wu, M. Maia, and S. Bonafonte Intravitreal bevacizumab (avastin((r))) for diabetic retinopathy at 24-months: the 2008 Juan Verdaguer-Planas lecture Curr Diabetes Rev 6 September (5) 2010 313 322
59. K. Nishijima, Y.S. Ng, L. Zhong, J. Bradley, W. Schubert, and N. Jo Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am J Pathol 171 July (1) 2007 53 67
60. I. Georgalas, D. Papaconstantinou, K. Papadopoulos, D. Pagoulatos, D. Karagiannis, and C. Koutsandrea Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease - a possible side effect? Curr Drug Saf 9 February (2) 2014 156 158
61. P. Fiorina, A.M. Shapiro, C. Ricordi, and A. Secchi The clinical impact of islet transplantation Am J Transplant 8 October (10) 2008 1990 1997
62. F. D'Addio, P. Maffi, P. Vezzulli, A. Vergani, A. Mello, and R. Bassi Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes Diabetes Care 37 January (1) 2014 267 276
63. P. Fiorina, P. Vezzulli, R. Bassi, C. Gremizzi, M. Falautano, and F. D'Addio Near normalization of metabolic and functional features of the central nervous system in type 1 diabetic patients with end-stage renal disease after kidney-pancreas transplantation Diabetes Care 35 February (2) 2012 367 374
64. J.M. Gregory, and D.J. Moore Can technological solutions for diabetes replace islet cell function? Organogenesis 7 January-March (1) 2011 32 41
65. S.W. Oh, S. Kim, K.Y. Na, D.W. Chae, D.C. Jin, and H.J. Chin Clinical implications of pathologic diagnosis and classification for diabetic nephropathy Diabetes Res Clin Pract 97 September (3) 2012 418 424
66. B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, and A.S. Krolewski Regression of microalbuminuria in type 1 diabetes N Engl J Med 348 June (23) 2003 2285 2293